HomeNewsBusinessEarningsNectar Lifesciences eyes Rs 1300cr topline in FY12

Nectar Lifesciences eyes Rs 1300cr topline in FY12

In an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and the road ahead.

January 17, 2011 / 17:40 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

Nectar Lifesciences has announced its third quarter number. Its Q3 net sales were at Rs 320 crore versus Rs 242 crore.

In an interview with CNBC-TV18
first published: Jan 17, 2011 04:53 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!